Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Research and development	$ 10,797	$ 7,594
General, and administrative	9,295	9,393
Operating expenses	20,092	16,987
Operating loss	(20,092)	(16,987)
Other income (expense):
Other income, net	740	824
Interest expense	0	(5)
Total other income (expense), net	740	819
Net loss	(19,352)	(16,168)
Less - net income (loss) attributable to noncontrolling interests	9	(1)
Net loss attributable to Caladrius Biosciences, Inc. common shareholders	$ (19,361)	$ (16,167)
Basic and diluted loss per share:
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders (in dollars per share)	$ (1.88)	$ (1.67)
Weighted average common shares outstanding:
Basic and diluted weighted average common shares outstanding (shares)	10,325	9,689